Form 4: United Therapeutics CEO Executes Planned Stock Sale

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• Following the exercise, the CEO sold the 9,500 shares in multiple transactions on May 27, 2026.
• The sales were executed at weighted average prices ranging from $570.81 to $579.59 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were conducted under a pre-arranged plan and represent routine liquidity management by the CEO.

Positives

• The transactions were part of a pre-planned 10b5-1 program, indicating the sales were not based on non-public information.
• The CEO maintains a significant remaining direct and indirect ownership stake in the company.

Negatives

• The transaction represents a reduction in the CEO's direct beneficial ownership of common stock.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of December 31, 2026, or the exercise of 1,734,410 stock options, which may lead to further periodic selling pressure.

Future Outlook

The reporting person's 10b5-1 plan remains active and is expected to continue until the end of 2026 or until the specified limit of 1,734,410 options is reached.

Management Comments

• The transactions were executed pursuant to a pre-arranged 10b5-1 trading plan adopted on November 7, 2025.

Industry Context

StockSavvy.ai notes that executive selling via 10b5-1 plans is a standard practice in the biotechnology sector, often used for liquidity and diversification, and generally does not signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard corporate governance practice for executives at large-cap biotech firms like Amgen, Gilead, and Biogen to avoid insider trading concerns.

Related Party Transactions

• The filing discloses various holdings in family trusts where the Reporting Person or their spouse share investment power or are beneficiaries.

Stakeholder Impact

• Shareholders should note the ongoing, scheduled nature of these sales, which provides transparency regarding future insider selling activity.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Biotech, Stock Options